Hosted on MSN9h
Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...
Business Wire22h
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
2minutemedicine.com5d
Twice-yearly lenacapavir prevents HIV more effectively than daily F/TDF or F/TAF
In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...
BMJ6d
Lenacapavir: a giant step forward in HIV prevention—but a missed opportunity for achieving equity and access
This year has seen a double dose of optimism in the field of HIV prevention. First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled ...
The American Journal of Managed Care10d
Lenacapavir Highly Effective in Preventing HIV
New data from the PURPOSE 2 trial continue to show the efficacy of lenacapavir in HIV prevention in individuals who have sex ...
Queerty on MSN11d
More good news about the twice-yearly PrEP injection
Lenacapavir is already in use as a treatment for HIV. However, pharma giant Gilead has been testing it as an injectable form ...
Managed Healthcare Executive6d
PrEP Overview in Light of Lenacapavir Licensing Agreements
Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...
News246d
Efficacy of 6-monthly HIV prevention jab confirmed in second major study
The second of two pivotal studies of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir ...
Star Observer12d
This Breakthrough Twice-Yearly Injection Shows 96% Efficacy Against HIV
Llenacapavir, a new HIV prevention injection, has been shown to have a 96% efficacy rate against the spread of the virus.
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) ...
Gilead reports updated data from trial of acclaimed HIV PrEP drug
Gilead is looking towards approval of lenacapavir as HIV PrEP after reporting near-perfect efficacy in the PURPOSE-1 and ...